Association between immune-related adverse events and recurrence dynamics under adjuvant anti-PD-1 therapy in resected melanoma.

ABSTRACT:

Introduction

Adjuvant anti-PD-1 therapy has significantly improved recurrence-free survival (RFS) in patients with resected high-risk melanoma, yet a substantial proportion still relapse. Identifying predictors of recurrence remains a clinical priority.

Methods

We retrospectively analyzed 84 patients with resected stage IIB-IV cutaneous melanoma who received adjuvant nivolumab or pembrolizumab. Clinicopathologic factors and immune-related adverse events (irAEs) occurring within the first 6 months of therapy were evaluated for their association with recurrence timing and RFS. Kaplan-Meier estimates, Cox regression models, and 3- and 6-month landmark analyses were used.

Results

After a median follow-up of 30.7 months, 48.8% of patients experienced recurrence, including

SUBMITTER: Sahin G 

PROVIDER: S-EPMC12634362 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature